WIA
SCPH

Wealthedge Investment Advisors’s scPharmaceuticals SCPH Stock Holding History

Wealthedge Investment Advisors’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36,569
Closed -$139K – 153
2025
Q2 		$139K Sell
36,569
-28,478
-44% -$88.4K 0.06% 140
2025
Q1 		$171K Buy
65,047
+45,667
+236% +$149K 0.08% 164
2024
Q4 		$68.6K Buy
+19,380
New +$74.2K 0.03% 166

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Wealthedge Investment Advisors's SCPH Position: Q3 2025 in Review

Wealthedge Investment Advisors sold out of scPharmaceuticals (SCPH) in Q3 2025, closing a stake of 36,569 shares — an estimated $139K sold.

Wealthedge Investment Advisors first reported a position in SCPH in Q4 2024 and held it in 3 quarters. The position peaked at $171K in Q1 2025. 110 funds tracked by Wall St. Rank hold SCPH as of Q3 2025.

  • Wealthedge Investment Advisors reported no remaining scPharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Wealthedge Investment Advisors sold 36,569 scPharmaceuticals shares in Q3 2025, an estimated $139K.
  • Wealthedge Investment Advisors first reported a position in scPharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Wealthedge Investment Advisors's scPharmaceuticals position peaked at $171K in Q1 2025.
  • 110 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2025.

Based on Wealthedge Investment Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.